Please use this identifier to cite or link to this item:
Title: Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results
Author: Moreno Grau, Sonia
Rodríguez Gómez, Octavio
Sanabria, Ángela
Pérez Cordón, Alba
Sánchez Ruiz, Domingo
Abdelnour, Carla
Valero, Sergi
Hernández, Isabel
Rosende-Roca, Maitée
Mauleón, Ana
Vargas, Liliana
Lafuente, Asunción
Gil, Silvia
Santos Santos, Miguel A.
Alegret, Montserrat
Espinosa, Ana
Ortega, Gemma
Guitart, Marina
Gailhajanet, Anna
Rojas, Itziar de
Sotolongo Grau, Óscar
Ruiz, Susana
Aguilera, Nuria
Papasey, Judith
Martín, Elvira
Peleja, Esther
Lomeña Caballero, Francisco Juan
Campos, Francisco
Vivas, Assumpta
Gómez Chiari, Marta
Tejero, Miguel Ángel
Giménez, Joan
Serrano Ríos, Manuel
Orellana, Adelina
Tárraga, Lluís
Ruiz, Agustín
Boada, Mercè
Alzheimer's Disease Neuroimaging Initiative
FACEHBI study group
Keywords: Malaltia d'Alzheimer
Malalties del sistema nerviós
Alzheimer's disease
Nervous system Diseases
Issue Date: 20-Nov-2017
Publisher: Wiley
Abstract: Introduction: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. Methods: We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta-analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts. Results: Analysis of the FACEHBI cohort and the meta-analysis demonstrated SCD individuals presented higher allelic frequencies of APOE ε4 with respect to controls. APOE dosage explained 9% (FACEHBI cohort) and 11% (FACEHBI and Alzheimer's Disease Neuroimaging Initiative cohorts) of the variance of cerebral amyloid levels. Discussion: The FACEHBI sample presents APOE ε4 enrichment, suggesting that a pool of AD patients is nested in our sample. Cerebral amyloid levels are partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this AD endophenotype.
Note: Reproducció del document publicat a:
It is part of: Alzheimer's & Dementia, 2017, vol. 14, p. 634-643
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
j.jalz.2017.10.005.pdf419.19 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons